July 2020, Drugs Monitor, Page 3

(13 July 2020) Hydroxychloroquine, lopinavir/Ritonavir- no difference was found between HCQ or LPV/r as compared to standard of care

July 14, 2020

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis https://doi.org/10.1186/s13054-020-03117-9 In this retrospective observational study, eighty patients were treated during a 4-week period and included in the analysis: 22 (28%)… Continue reading "(13 July 2020) Hydroxychloroquine, lopinavir/Ritonavir- no difference was found between HCQ or LPV/r as compared to standard of care"

(11 July 2020) Hydroxychloroquine- Clinical trials data fails to demonstrate evidence of shortened viral shedding

July 11, 2020

A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19) https://doi.org/10.1101/2020.07.08.20148841 The efficacy of hydroxychloroquine (HCQ) against coronavirus disease 2019 (COVID-19)… Continue reading "(11 July 2020) Hydroxychloroquine- Clinical trials data fails to demonstrate evidence of shortened viral shedding"

(10 July 2020) Tocilizumab- early use reduced need of MV

July 11, 2020

Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. https://doi.org/10.1002/jmv.26288 In this longitudinal observational study, 112 patients were evaluated from 2/1/2020 – 5/31/2020. TCZ was administered… Continue reading "(10 July 2020) Tocilizumab- early use reduced need of MV"

(09 July 2020) Tocilizumab- non-negligible proportion of deaths due to life-threatening hepatic reactions

July 10, 2020

Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.14459 To characterize serious adverse events (AEs) with tocilizumab, authors queried the worldwide FDA Adverse Event Reporting System and perform disproportionality analysis, selecting only designated medical… Continue reading "(09 July 2020) Tocilizumab- non-negligible proportion of deaths due to life-threatening hepatic reactions"

(08 July 2020) Ivermectin- add on use to HCQ and AZT improved effectiveness

July 9, 2020

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1 This Pilot clinical trial was conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of… Continue reading "(08 July 2020) Ivermectin- add on use to HCQ and AZT improved effectiveness"

(07 July 2020) Tocilizumab- limited clinical improvement in patients

July 8, 2020

Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis https://doi.org/10.1002/jmv.26191 This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48,… Continue reading "(07 July 2020) Tocilizumab- limited clinical improvement in patients"

(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate

July 7, 2020

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series https://doi.org/10.1186/s13054-020-03078-z This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to… Continue reading "(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate"

(06 July 2020) Hydroxychloroquine- use of hydroxychloroquine alone and in combination with azithromycin was associated with significant reduction in-hospital mortality

July 7, 2020

Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19 https://doi.org/10.1016/j.ijid.2020.06.099 Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with… Continue reading "(06 July 2020) Hydroxychloroquine- use of hydroxychloroquine alone and in combination with azithromycin was associated with significant reduction in-hospital mortality"

(05 July 2020) Lopinavir/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)

July 7, 2020

Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study https://doi.org/10.1002/jmv.26260 This is a retrospective study of 128 hospitalized patients with COVID-19 pneumonia. All patients were positive severe acute respiratory syndrome coronavirus 2… Continue reading "(05 July 2020) Lopinavir/Ritonavir- associated with faster pneumonia resolution within two weeks after symptom onset (37% vs 1%, P=0.001)"

(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC

July 7, 2020

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study https://ard.bmj.com/content/early/2020/07/03/annrheumdis-2020-218122 In an open-label study of sarilumab in severe COVID-19 pneumonia (PaO2/FiO2 <300 mm Hg) with hyperinflammation (elevated inflammatory markers and serum IL-6 levels), sarilumab… Continue reading "(04 July 2020) Sarilumab- At day 28, not significant difference between sarilumab and SoC"

Month: July 2020